Botulinum toxin A - Daewoong Pharmaceuticals

Drug Profile

Botulinum toxin A - Daewoong Pharmaceuticals

Alternative Names: DWP-450; Evosyal; Nabota; Prabotulinumtoxin A

Latest Information Update: 30 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Daewoong Pharmaceutical
  • Developer ALPHAEON Corporation; Daewoong Pharmaceutical
  • Class Antispasmodics; Bacterial proteins; Bacterial toxins; Botulinum toxins; Muscle relaxants
  • Mechanism of Action Acetylcholine inhibitors; Glutamate-antagonists; Neuromuscular blocking agents
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Glabellar lines
  • Phase III Muscle spasticity
  • Phase II/III Blepharospasm; Facial-wrinkles

Most Recent Events

  • 26 Oct 2017 Preregistration for Glabellar lines in Canada (Parenteral)
  • 26 Oct 2017 Health Canada accepts New Drug Submission for Botulinum toxin A for Glabellar lines for review
  • 09 Oct 2017 Efficacy and adverse events data from EV-001, EV-002 and EV-006 trials in Glabellar lines released by Evolus
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top